CN117599151B - 益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途 - Google Patents
益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途 Download PDFInfo
- Publication number
- CN117599151B CN117599151B CN202311702895.9A CN202311702895A CN117599151B CN 117599151 B CN117599151 B CN 117599151B CN 202311702895 A CN202311702895 A CN 202311702895A CN 117599151 B CN117599151 B CN 117599151B
- Authority
- CN
- China
- Prior art keywords
- heart failure
- chronic heart
- active peptide
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 34
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 31
- 230000036772 blood pressure Effects 0.000 claims abstract description 11
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims abstract description 6
- 206010038464 renal hypertension Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 9
- 244000248557 Ophiopogon japonicus Species 0.000 claims description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 5
- 230000003205 diastolic effect Effects 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 5
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 229930195210 Ophiopogon Natural products 0.000 claims description 4
- 240000007164 Salvia officinalis Species 0.000 claims description 4
- 240000006079 Schisandra chinensis Species 0.000 claims description 4
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 235000005412 red sage Nutrition 0.000 claims description 4
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 abstract description 10
- 230000004217 heart function Effects 0.000 abstract description 7
- 238000007634 remodeling Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 18
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 5
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 5
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 description 3
- 240000000171 Crataegus monogyna Species 0.000 description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 3
- 241000212322 Levisticum officinale Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000001645 levisticum officinale Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100030805 Adropin Human genes 0.000 description 1
- 101710161788 Adropin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 101000650158 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP1 Proteins 0.000 description 1
- 101001024635 Homo sapiens RNA cytidine acetyltransferase Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 102100027550 NEDD4-like E3 ubiquitin-protein ligase WWP1 Human genes 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102100037011 RNA cytidine acetyltransferase Human genes 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003825 ivabradine Drugs 0.000 description 1
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明的目的在于提供一种益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途，尤其是用于预防和/或治压力负荷诱导的心肌肥厚和心力衰竭，如肾性高血压诱导的慢性心力衰竭，大幅度降低了死亡率，在可接受范围内降低血压，可以有效改善心脏功能，减缓心脏重塑进程，减慢进入心力衰竭阶段的速度。
Description
技术领域
本发明涉及医药生物领域，具体涉及益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途。
背景技术
益心舒丸(微丸)出于金元时代李杲(字明之，晚号东垣老人)所著的《内外伤辨惑论》(生脉饮同出于此论)。由人参、麦冬、五味子组成。
方中人参补脾益气以生津为主，辅以麦冬养阴清热以生津，五味子敛肺止汗而生津，共成益气养阴，生津止渴，固表止汗之功，为治热伤气阴的常用方剂。在此基础上加入了丹参，黄芪，川芎及山楂四味药，方中人参大补元气以生津，丹参活血化瘀以复脉，共为本方主药，为君；黄芪益气补虚，麦冬养阴生津，川芎活血行气，辅助两君药益气活血，共为臣药，五味子补益心气，山楂降脂活血，共为佐药。诸药合方，共建益气复脉，活血化瘀，养阴生津之功效。用于气阴两虚，心悸脉结代，胸闷不舒、胸痛及冠心病、心绞痛见有上述症状者。
益心舒的作用已经被临床验证，但是也存在药效显著性等方面的问题。因此，临床中开始进行联合用药，有文献报道了心绞痛、早搏、动脉硬化方面的联合用药，也有慢性心力衰竭方面的报道(参考吕杰等，益心舒片联合曲美他嗪治疗对慢性心力衰竭心功能参数及Adropin蛋白水平的影响，中国临床保健杂志，第06期，第70-73页，2019；朱改针等，伊伐布雷定联合益心舒片对稳定型心绞痛患者血管内皮细胞功能的影响，中西医结合研究，第04期，第10-12页，2020；张昊洲，益心舒片联合尼可地尔治疗冠心病心绞痛患者的临床疗效，中国药物与临床，第05期，第96-98页，2020；孙政，益心舒片联合炙甘草汤与西药治疗频发性室性早搏临床研究，新中医，第15期，第87-90页，2020.08.05；薛仁洪，美益康益心舒片治疗稳定性心绞痛的临床疗效及对动脉硬化程度的影响，中国处方药，第02期，第68-69页，2020)。
具有活性的多肽称为活性肽，又称生物活性肽或生物活性多肽。活性肽在人的生长发育，新陈代谢，疾病以及衰老，死亡的过程中起着关键作用。活性肽是人体中最重要的活性物质。正是因为它在体内分泌量的增多或减少，才使人类有了幼年，童年，成年，老年直到死亡的周期。而注射活性肽便打破了生命的这一周期，从而达到延长生命，有效减缓衰老的神奇效果。因此，活性肽变成科学家炙手可热的研究对象。通过生物信息学结合计算机模拟，考虑了脑钠肽，肌钙蛋白，肌红蛋白等常见的蛋白，也考虑了WWP1、NAT10、Apo O等新发现的相关基因，得到了得分最高的活性肽MFGHVQAAMF。
因此，本发明提出了将益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途。尤其是用于预防和/或治压力负荷诱导的心肌肥厚和心力衰竭，如肾性高血压诱导的慢性心力衰竭，大幅度降低了死亡率，在可接受范围内降低血压，可以有效改善心脏功能，减缓心脏重塑进程，减慢进入心力衰竭阶段的速度。
发明内容
本发明提供一种益心舒片联合活性肽在制备用于预防和/或治疗慢性心力衰竭的药物中的用途，所述益心舒片含有人参、麦冬、五味子、黄芪、丹参、川芎、山楂以及药用辅料，所述活性肽的氨基酸序列为MFGHVQAAMF。
其中慢性心力衰竭是肾脏疾病导致的肾性高血压诱导的；
其中预防和/或治疗慢性心力衰竭包括降低死亡率；
其中预防和/或治疗慢性心力衰竭包括降低肾性高血压的血压；
其中预防和/或治疗慢性心力衰竭包括改善心脏功能；
其中预防和/或治疗慢性心力衰竭包括减缓心脏重塑进程；
其中预防和/或治疗慢性心力衰竭包括减慢进入心力衰竭阶段的速度；
其中预防和/或治疗慢性心力衰竭包括改善心肌肥厚；
其中预防和/或治疗慢性心力衰竭包括改善慢性心力衰竭相关的呼吸症状；
其中预防和/或治疗慢性心力衰竭包括心脏收缩舒张功能。
本发明的有益效果是：本发明提出了将益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途。尤其是用于预防和/或治压力负荷诱导的心肌肥厚和心力衰竭，如肾性高血压诱导的慢性心力衰竭，大幅度降低了死亡率，在可接受范围内降低血压，可以有效改善心脏功能，减缓心脏重塑进程，减慢进入心力衰竭阶段的速度。
具体实施方式
下面结合实施例对本发明的实施方式作更进一步的说明。
实施例1：动物实验
取发育整齐、生长性能一致、体重为150-200g左右的血压正常的SD大鼠90只，使其自由摄食及饮水。适应性喂养一周后，根据血压对大鼠进行随机分组，分为空白(30只，其中15只进行假手术，由于假手术不影响大鼠功能，后续结果都计入空白组)和需要做手术的组(60只)，做两肾一夹手术，术后2周将其分为模型对照组(15只)，50mg/kg益心舒片(15只)，50mg/kg活性肽(15只)，25mg/kg益心舒片联合25mg/kg活性肽(15只)，灌胃给药或者给水一天一次，术前8小时禁食不禁水。培养第20周处死压力负荷诱导的心肌肥厚及心力衰竭模型大鼠。
血压及心率测试结果：第2/6/12/16周，采用智能无创血压计检测监测大鼠麻醉状态下右前肢血压变化，得到心率(Heart rate HR，单位次/分)，收缩压(SBP，单位mmHg)，舒张压(DBP，单位mmHg)，各组心率变化无规律。结果见表1和2，取整数。
表1SBP测量结果
表2DBP测量结果
结果显示，活性肽在可接受范围内降低血压，无过山车式波动，尤其是益心舒片联合活性肽显示协同降压作用，且作用效果优于单独使用。
收缩舒张功能：第14周采用彩色多普勒超声实时心脏影像测定EF和FS，并观察心脏形态，结果见表3，取整数。
表3EF和FS测量结果
结果显示，益心舒片和活性肽可以有效改善心脏功能，尤其是益心舒片联合活性肽显示协同改善心脏收缩舒张功能作用，且作用效果优于单独使用。
血流动力学测试结果：第20周采用生物机能实验系统测定，测完处死，心率(Heartrate HR，单位次/分)，收缩压(SBP，单位mmHg)，舒张压(DBP，单位mmHg)，左室发展压LVDP＝LVSP-LVEDP，单位mmHg、左室压力变化最大上升速率(+dP/dtmax)、左室压力变化最大下降速率(-dP/dtmax)，结果取整数，见表4。各组心率变化无规律。
表4血流动力学测试结果
结果显示，益心舒片和活性肽可以有效改善心脏功能，减缓心脏重塑进程，减慢进入心力衰竭阶段的速度，尤其是益心舒片联合活性肽显示协同改善心脏收缩舒张功能作用，且作用效果优于单独使用。
BNP的含量：采用试剂盒测定各组实验动物心脏中血清BNP的含量，结果取整数，见表6。
表6血清BNP的含量
| BNP(ng/ml) | |
| 空白组 | 17±1 |
| 模型对照组 | 38±4 |
| 益心舒片 | 26±3 |
| 活性肽 | 23±2 |
| 益心舒片联合活性肽 | 20±2 |
死亡率：记录整个过程中各组动物死亡情况，结果见表7。
表7各组动物死亡情况
结果显示，益心舒片和活性肽可以有效降低了死亡率，尤其是益心舒片联合活性肽显示协同大幅度降低了死亡率，这对心衰患者至关重要。
以上实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (5)
1.益心舒片联合活性肽在制备用于预防和/或治疗慢性心力衰竭的药物中的用途，所述益心舒片含有人参、麦冬、五味子、黄芪、丹参、川芎、山楂以及药用辅料，所述活性肽的氨基酸序列为MFGHVQAAMF，其中慢性心力衰竭是肾脏疾病导致的肾性高血压诱导的。
2.根据权利要求1所述益心舒片联合活性肽在制备用于预防和/或治疗慢性心力衰竭的药物中的用途，其中预防和/或治疗慢性心力衰竭包括降低死亡率。
3.根据权利要求1所述益心舒片联合活性肽在制备用于预防和/或治疗慢性心力衰竭的药物中的用途，其中预防和/或治疗慢性心力衰竭包括降低肾性高血压的血压。
4.根据权利要求1所述益心舒片联合活性肽在制备用于预防和/或治疗慢性心力衰竭的药物中的用途，其中预防和/或治疗慢性心力衰竭包括改善心肌肥厚。
5.根据权利要求1所述益心舒片联合活性肽在制备用于预防和/或治疗慢性心力衰竭的药物中的用途，其中预防和/或治疗慢性心力衰竭包括心脏收缩舒张功能。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311702895.9A CN117599151B (zh) | 2023-12-12 | 2023-12-12 | 益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311702895.9A CN117599151B (zh) | 2023-12-12 | 2023-12-12 | 益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117599151A CN117599151A (zh) | 2024-02-27 |
| CN117599151B true CN117599151B (zh) | 2024-04-30 |
Family
ID=89946231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311702895.9A Active CN117599151B (zh) | 2023-12-12 | 2023-12-12 | 益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117599151B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015139532A1 (zh) * | 2014-03-18 | 2015-09-24 | 张喜田 | 重组灵芝免疫调节蛋白(rLZ-8)在制备治疗慢性心力衰竭药物中的应用 |
-
2023
- 2023-12-12 CN CN202311702895.9A patent/CN117599151B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015139532A1 (zh) * | 2014-03-18 | 2015-09-24 | 张喜田 | 重组灵芝免疫调节蛋白(rLZ-8)在制备治疗慢性心力衰竭药物中的应用 |
Non-Patent Citations (4)
| Title |
|---|
| Lauren B. Arendse等.Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.Pharmacol Rev.第71卷第539-570页. * |
| 中药抑制炎症标志物干预慢性心力衰竭的研究进展;全振华;刘莉;艾民;金娟;;国际检验医学杂志;20160430(08);第1092-1094页 * |
| 益心舒片联合曲美他嗪治疗对慢性心力衰竭心功能参数及Adropin蛋白水平的影响;吕杰;刘在美;;中国临床保健杂志;20191231;22(6);第783-786页 * |
| 益心舒胶囊对慢性充血性心力衰竭患者心功能及血浆脑钠肽的影响;王慧等;中西医结合心脑血管病杂志;20140430;第12卷(第4期);第409-410页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117599151A (zh) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101493016B1 (ko) | 중약 조성물의 새로운 용도 | |
| CN101011496A (zh) | 一种活血化瘀茶 | |
| CN108524673A (zh) | 一种中药组合物及其应用 | |
| CN111686185A (zh) | 治疗扩张型心肌病的中药组合物及其制备方法 | |
| CN117599151B (zh) | 益心舒片联合活性肽预防和/或治疗慢性心力衰竭的用途 | |
| US20090208596A1 (en) | Medical Herb Composition for the Alleviation of Cardiopulmonary Ailments or the Improvement of Cardiopulmonary Function in a Mammal | |
| CN1762441A (zh) | 一种治疗高血脂的中药组合物及其制备方法 | |
| WO2016124080A1 (zh) | 20(R)-人参皂苷Rg3在制备预防或/和治疗肥胖症药物中的应用及药物 | |
| CN103239470B (zh) | 一种含鸡腿蘑多糖和香菇多糖的双菇多糖组合物及其制法和用途 | |
| JP2021518852A (ja) | 心血管疾患又は脳血管疾患を治療する漢方薬組成物及びその調製方法並びに使用 | |
| CN101804075B (zh) | 海星在制备治疗骨质疏松症的药物中的应用 | |
| CN109758497B (zh) | 用于慢性心力衰竭的中药组合物、药物及其制备方法和应用 | |
| CN102861232A (zh) | 一种中药组合物在制备治疗高血压的药物中的应用 | |
| CN102225082B (zh) | 一种防治糖尿病及其并发症的药物和其制备方法 | |
| CN106620253B (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
| CN109892599A (zh) | 一种供冠心病人群食用的药膳 | |
| CN100356952C (zh) | 一种治疗心力衰竭的中药组合物及其口服制剂 | |
| CN110693035A (zh) | 一种供骨质疏松人群食用的含肽组合物及应用 | |
| CN1718191A (zh) | 人参总次苷口腔崩解片及其制备方法和应用 | |
| CN114767794B (zh) | 一种治疗动脉斑块的中药 | |
| CN114848775B (zh) | 一种治疗急性期心肌梗死的中药组合物及其中药制剂和应用 | |
| CN108066373A (zh) | 一种防治2型糖尿病的药物及制备方法 | |
| CN107551217B (zh) | 促进肌质网钙泵表达而治疗慢性心力衰竭中药组合物配方 | |
| KR20050072625A (ko) | 골다공증 개선 및 예방용 조성물 | |
| CN105833001B (zh) | 参芪降糖颗粒在制备糖尿病性心脏病药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |